At 8.0% CAGR, the North America Drug Delivery Market is projected to be worth US$ 14,29,417.79 million by 2028, says Business Market Insights

According to Business Market Insights research, the North America drug delivery market was valued at US$ 9,74,639.53 million in 2023 and is expected to reach US$ 14,29,417.79 million by 2028, registering a CAGR of 8.0% from 2023 to 2028. Rising incidence of chronic diseases, growing demand for noninvasive drug delivery systems, and increasing R&D expenditures in pharmaceutical companies are the critical factors attributed to the North America drug delivery market expansion.        

Noninvasive drug delivery generally refers to methods of painless drug delivery across the biological barriers of mucosal surfaces or skin. This drug delivery method could lead to improved access to medicines, adherence to treatment regimes, and better drug safety profiles. Patients prefer noninvasive drug delivery routes due to such apparent advantages over injection-based drug administration. Patient compliance has been found to be much higher when drugs are administrated by noninvasive methods, as they experience decreased pain during the procedure. With improvements in medical devices and transdermal delivery technologies, the noninvasive mode of drug delivery is now ready to compete with traditional methods of oral and injectable routes of drug delivery. Topical, transdermal-active (device-aided enhanced penetration), transdermal-passive, trans-ocular membrane, trans-mucosal membrane, and delivery via an alveolar membrane from inhaled medication are a few of the popular noninvasive drug delivery methods. Drug delivery through noninvasive methods involves reduced dosing frequency and simplified dosing schedules. Moreover, these delivery systems can significantly reduce the cost of clinical use as patients can self-administer drugs via these methods. In many cases, the manufacturing cost of drugs with noninvasive delivery systems is lesser than the production costs of injections. For instance, inhaled insulin has emerged as a well-tolerated and preferred modality for treating diabetes. Thus, the growing demand for noninvasive drug delivery systems propels the growth of the North America drug delivery systems market.

On the contrary, high cost associated with development of drugs and delivery systems hampers the North America Drug Delivery Market.  

Based on route of administration, the North America drug delivery market is segmented into injectable drug delivery, oral drug delivery, transmucosal drug delivery, topical drug delivery, implantable drug delivery, and ocular drug delivery. The injectable drug delivery segment held 45.6% share of North America Drug Delivery Market in 2023, amassing US$ 4,44,832.82 million. It is projected to garner US$ 6,25,921.77 million by 2028 to expand at 7.1% CAGR during 2023–2028. 

Based on distribution channel, the North America drug delivery market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 69.2% share of North America Drug Delivery Market in 2023, amassing US$ 6,74,831.50 million. It is projected to garner US$ 10,06,938.14 million by 2028 to expand at 8.3% CAGR during 2023–2028.

Based on end user, the North America drug delivery market is segmented into hospitals and clinics, home care settings, and other end user. The hospitals and clinics segment held 55.5% share of North America Drug Delivery Market in 2023, amassing US$ 5,40,869.66 million. It is projected to garner US$ 8,15,912.77 million by 2028 to expand at 8.6% CAGR during 2023–2028.

Based on country, the North America drug delivery market  has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 85.7% share of North America Drug Delivery Market in 2023. It was assessed at US$ 8,35,182.54 million in 2023 and is likely to hit US$ 12,33,873.43 million by 2028, exhibiting a CAGR of 8.1% during the forecast period.      

Key players dominating the North America drug delivery market are Bausch Health Companies Inc; Baxter International Inc.; Becton Dickinson and Co; Boehringer Ingelheim International GmbH; Boston Scientific Corp; Gerresheimer AG; GlaxoSmithKline Plc; Johnson & Johnson; Kindeva Drug Delivery LP; Novartis AG; Novo Nordisk AS; Pfizer Inc; and Sever Pharma Solutions, among others.   

• In April 2023, Baxter International Inc. announced the U.S. launch of ZOSYN (piperacillin and tazobactam) Injection. Zosyn premix is indicated for treating multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers. Baxter sells Zosyn premix in 2.25 g in 50 mL, 3.375 g in 50 mL, and 4.5 g in 100 mL presentations.
• In October 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. FDA has approved TECVAYLI (teclistamab-cqyv) for treating adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy. TECVAYLI is a first-in-class, bispecific T-cell engager antibody administered as a subcutaneous treatment. TECVAYLI is Janssen’s fourth approved treatment for multiple myeloma that further diversifies the company’s industry-leading oncology portfolio.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com